Abstract
National registers showed that a large proportion of patients treated with strontium ranelate have conditions that may now contraindicate use. The risk of death in strontium ranelate-treated patients was significantly higher than that seen in users of other osteoporosis drugs even after adjusting for cardiovascular risk factor profile.
Original language | English |
---|---|
Journal | Osteoporosis International |
Volume | 25 |
Issue number | 2 |
Pages (from-to) | 757-762 |
Number of pages | 6 |
ISSN | 0937-941X |
DOIs | |
Publication status | Published - Feb 2014 |